From Delay to Damage

Target Audience

This activity is intended for rheumatologists and other specialists (eg, pulmonologists, allergists/clinical immunologists) who manage patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Program Overview

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare autoimmune small-vessel vasculitis that has a complex phenotype with symptomatology that affects multiple organ systems. Join us for this engaging Expert Insights program to learn more about EPGA, an intriguing heterogeneous multisystem disease plagued by delays in diagnosis – and the effective targeted biologic therapies that are now available to treat this disease. Along with a whiteboard animation, multidisciplinary faculty will review the pathophysiologic processes underlying EGPA development, best approaches for prompt diagnosis, and strategies for individualizing therapeutic regimens that improve patient outcomes. You don’t want to miss this informative and thought-provoking session!

Educational Objectives 

After completing this activity, the participant should be better able to:

1. Describe the pathophysiologic causes and biopsychosocial consequences of EGPA
2. Identify patients with EGPA quickly based symptoms, laboratory testing, and ruling out other potential disorders
3. Discuss the clinical rationale and trial evidence for biologic treatment options for patients with EGPA
4. Construct biologic-based regimens for patients with EGPA to address underlying pathophysiologic processes, reduce corticosteroid exposure, and target remission

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com. 

Instructions to Receive Credit

In order to receive credit for this activity, the participant must attend the live symposium/live stream and complete the posttest and program evaluation. 

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Brian D. Jaros, MD:

Consulting Fees: Novartis; Contracted Research: Abbvie; Contracted Research: Amgen

Philip Seo, MD, MHS:

Non-CE Services: Amgen

Michael E. Wechsler, MD, MMSc:

Consulting Fees: Allakos, Amgen, Areteia Therapeutics, Arrowhead Pharmaceutical, AstraZeneca, Avalo Therapeutics, Belenos Bio, Celldex, Connect Biopharma, Eli Lilly, Equillium, Glaxosmithkline, Incyte, Jasper Therapeutics, Kinaset, Kymera, Merck, MyBiometry, Pharming, Phylaxis, Pulmatrix, Rapt Therapeutics, recludix Pharma, Roche/Genentech, Regeneron, Sanofi/Genzyme, Sentien, Sound Biologics, Tetherex Pharmaceuticals, Uniquity Bio, Upstream Bio, Verona Pharma, Zurabio; Stock Options: Upstream Bio

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.